Imunofan nasal spray 50mcg/dose 40dose

Pharmacological properties
The drug has an immunoregulatory, detoxification, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. Pharmacological action is based on the achievement of three main effects: correction of the immune system, restoring the balance of the oxidative-antioxidant reaction of the body and inhibition of multidrug resistance mediated by proteins of the transmembrane cell transport pump.

The action of the drug begins to develop within 2 to 3 hours (fast phase) and lasts up to 4 months (medium and slow phases).

During the fast phase (duration - up to 2-3 days), the detoxification effect is manifested primarily - the antioxidant protection of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol and production of inflammatory mediators. In case of toxic and infectious liver damage, the drug prevents cytolysis, reduces transaminase activity and serum bilirubin level.

During the middle phase (starts in 2-3 days, duration - up to 7-10 days), there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses. During the slow phase (it starts developing at 7-10 days, duration up to 4 months), immunoregulatory action of Imunofan is manifested - restoration of impaired indicators of cellular and humoral immunity. During this period, normalization of the immuno-regulatory index is observed, an increase in the production of specific antibodies is noted. The effect of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of some therapeutic vaccines. Unlike the latter, the drug has no significant effect on the production of reagin antibodies of the IgE class and does not enhance the immediate-type hypersensitivity reaction; Imunofan stimulates the formation of IgA in its congenital insufficiency.

Imunofan effectively suppresses the multidrug resistance of tumor cells and increases their sensitivity to the action of cytotoxic drugs.

Indications for use
Used in adults and children older than 2 years for the prevention and treatment of immunodeficiency and toxic conditions, acute and chronic infectious and inflammatory diseases.

Contraindications.
Hypersensitivity, children up to 2 years.

Dosage and recommended doses.
Intranasal. When using the bottle should be held vertically, spray up. Remove protective cap from sprayer.Before the first use, fill the metering pump by pressing the wide rim of the sprayer 3-4 times. Insert the nebulizer into the nasal passage with the head upright. Press the wide rim of the spray gun once to stop. A single dose of the drug contains 50 mcg of imunofan. The daily dose should not exceed 200 mg.

In the complex therapy of acute and chronic infectious and inflammatory diseases, accompanied by symptoms of intoxication and immunodeficiency, imunofan is prescribed in 1 dose (50 μg) in each nasal passage 2 times a day, daily for 10-15 days. For opportunistic infections (cytomegalovirus and herpes infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis):

• 1 dose (50 mcg) in each nasal passage 2 times a day, every day, a course of treatment 10 - 15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

In chronic viral hepatitis and chronic brucellosis:

• 1 dose (50 mcg) in each nasal passage 1 time a day, every day, a course of treatment 10 to 15 days, to prevent relapse, repeat courses should be conducted after 4 to 6 months.

In the scheme of treatment of patients with HIV infection:

• 1 dose (50 mcg) in each nasal passage 1 time a day, every day, for 10-15 days. If necessary, it is possible to repeat the course in 2-4 weeks.

When treating cancer patients in the scheme of radical combined treatment (chemo-radiation therapy and surgery):

• 1 dose (50 mcg) in each nasal passage 1 time a day, daily, for 8-10 days before chemo-radiation therapy and surgery, followed by continuing the course during the entire period of treatment.

In patients with a common tumor process (stage III - IV) of various localization in terms of complex or symptomatic therapy:

• 1 dose (50 mcg) in each nasal passage 1 time a day, every day, for 8-10 days.

If necessary, and the presence of pronounced effects of toxicosis, it is recommended to repeat the course.

Side effect.
Individual intolerance is possible.

Warning.
As a result of the activation of phagocytosis, a short-term exacerbation of the foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Interaction with other drugs.
Increases the effectiveness of other types of drug therapy: the use of Imunofan helps to overcome the resistance to glucocorticosteroid therapy. Administration of imunofan is possible in combination with steroid and non-steroid anti-inflammatory drugs.

Special instructions.
Due to insufficient knowledge, caution should be used during pregnancy and lactation.

Form release.
Imunofan®, nasal spray dosed at 50 mcg / dose. 40 doses in plastic bottles with a capacity of 10 ml. The bottles are sealed with lids fitted with a dosing pump with a plastic casing, a nozzle and a protective cap or similar dosing device. One bottle together with the application instruction is placed in a pack from a cardboard.

Storage conditions.
In the dark place at a temperature of from 2 ° C to 10 ° C